Jean Robey, MD
Nephrology · Sun City, AZNPI 1255377800
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.2%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Travere Therapeutics, Inc. at 45.2% of the total. 2025 is the largest year on record at $9,227, more than ten times the $254 reported in 2019. Among nephrology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 242 payments — averaging $73.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$8K
- AstraZeneca$4K
- Akebia Therapeutics Inc$2K
- Amgen$738
- Mallinckrodt Hospital Products Inc.$451
- OPKO Pharmaceuticals, LLC$404
- plus $2K from 21 others
What the payments were for
- Consulting fees$8,70249%
- Speaking & faculty fees$1,80010%
- Travel & lodging$2712%
- Food & beverage$6,60937%
- Education$3012%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 27 | $7,988 |
| AstraZeneca | 47 | $4,093 |
| Akebia Therapeutics Inc | 9 | $1,926 |
| Amgen(2 entities) | 37 | $738 |
| Mallinckrodt Hospital Products Inc. | 21 | $451 |
| OPKO Pharmaceuticals, LLC | 21 | $404 |
| Vifor Pharma, Inc. | 9 | $284 |
| Calliditas Therapeutics US Inc. | 8 | $230 |
| Pfizer | 2 | $206 |
| Otsuka America Pharmaceutical, Inc. | 9 | $175 |
| Lilly USA, LLC | 8 | $169 |
| Novartis | 7 | $156 |
| Bayer | 4 | $147 |
| GSK | 9 | $136 |
| Boehringer Ingelheim | 5 | $116 |
| Ultragenyx Pharmaceutical Inc. | 5 | $100 |
| Nxstage Medical, Inc. | 1 | $85 |
| Cormedix Inc. | 2 | $45 |
| Novo Nordisk | 2 | $42 |
| Daiichi Sankyo Inc. | 2 | $39 |
| Abbott | 1 | $26 |
| ANI Pharmaceuticals, Inc. | 1 | $26 |
| Renalytix AI, Inc. | 1 | $25 |
| Aurinia Pharma U.S., Inc. | 1 | $24 |
| Ardelyx, Inc. | 1 | $20 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,683 in reported general payments places this provider in the 95th percentile of 259 nephrology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 279 | $250,077 |
| TarpeyoBudesonide | 12 | $194,295 |
| TavneosAvacopan | 11 | $175,707 |
| FilspariSparsentan | 12 | $134,293 |
| LokelmaSodium Zirconium Cyclosilicate | 92 | $84,382 |
| VelphoroSucroferric Oxyhydroxide | 30 | $73,685 |
| KerendiaFinerenone | 33 | $37,102 |
| EliquisApixaban | 15 | $18,488 |
| EntrestoSacubitril/Valsartan | 11 | $13,713 |
| Sevelamer Carbonate | 46 | $12,857 |
| JardianceEmpagliflozin | 13 | $12,198 |
| DapagliflozinDapagliflozin Propanediol | 14 | $7,750 |
| Cinacalcet Hcl | 28 | $6,429 |
| Tacrolimus | 18 | $6,303 |
| Mycophenolate Mofetil | 19 | $3,552 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $4,093 | $334,459371 claims |
| Calliditas Therapeutics US Inc.Tarpeyo | $230 | $194,29512 claims |
| AmgenTavneos | $738 | $175,70711 claims |
| Travere Therapeutics, Inc.Filspari | $7,988 | $134,29312 claims |
| BayerKerendia | $147 | $37,10233 claims |
| PfizerEliquis | $206 | $18,48815 claims |
| NovartisEntresto | $156 | $13,71311 claims |
| Boehringer IngelheimJardiance | $116 | $12,19813 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $26 | $1,35235 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 259 nephrology providers in Arizona.
Other nephrology in Sun City
- Liqun BaiSun City$15K
- Randy CooperPeoria$597K
- Minesh RajpalPeoria$403K
- Umar WaheedPeoria$150K
- Amer KhanPeoria$71K
- Samer Bani HaniPhoenix$54K
- Aneesha ShettyTucson$34K
- Leslie ThomasPhoenix$22K
- Alexander NimriPhoenix$21K
- Saeed ShaffiScottsdale$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.